Osteoarthritis: aspects of pharmacotherapy

QR Code

Osteoarthritis: aspects of pharmacotherapy

The main goal of management of patients with osteoarthritis (OA) is analgesic and anti-inflammatory therapy, deceleration of the progression of the disease, and improvement of quality of life. Fast-acting symptomatic drugs (analgesics and nonsteroidal anti-inflammatory drugs (NSAIDs)) and sustained-...

Full description

Saved in:

Bibliographic Details
Main Authors:	L. N. Denisov, A. I. Platova, I. V. Menshikova, A. M. Lila
Format:	Article
Language:	Russian
Published:	IMA-PRESS LLC 2018-06-01
Series:	Современная ревматология
Subjects:	osteoartritis chondroprotectors preclinical trials efficacy tolerance
Online Access:	https://mrj.ima-press.net/mrj/article/view/833
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

CHONDROPROTECTIVE DRUG ALFLUTOP IN THE TREATMENT OF OSTEOARTHRITIS
by: G V Lukina, et al.
Published: (2001-04-01)

Computational linguistics and sentiment analysis of misconceptions in pharmacotherapy of osteoarthritis pain
by: I. Yu. Torshin, et al.
Published: (2023-09-01)

HUBUNGAN HIPERTENSI DENGAN DERAJAT DEFEK KERUSAKAN KARTILAGO OSTEOARTRITIS LUTUT BERDASARKAN ULTRASONOGRAFI
by: Sulung Ade Pratama, et al.
Published: (2019-02-01)

PERBEDAAN JENIS TOTAL KNEE ARTHROPLASTY TERHADAP DERAJAT FUNGSIONAL LUTUT DAN KUALITAS HIDUP PASIEN OSTEOARTHRITIS LUTUT
by: Ade Pratama Agung, et al.
Published: (2017-03-01)

Prescripción de glucosamina para la osteoartritis y sus efectos en personas con diabetes
by: Levi González Rivero
Published: (2012-02-01)

ZONEGRAN. NEW IN EVIDENTIAL PHARMACOTHERAPY OF EPILEPSY: OPPORTUNITIES AND EXPECTATIONS
by: I. G. Rudakova
Published: (2016-05-01)

PRECLINICAL AND CLINICAL ASPECTS OF THE DEVELOPMENT OF BIOMEDICAL CELL PRODUCTS
by: A. V. Tikhomirova, et al.
Published: (2018-03-01)

Experience in the use of a modern chondroprotector in patients with primary and secondary osteoarthritis of various localization in the acute stage
by: A. G. Khanov
Published: (2023-07-01)

Standardised Forms of Chondroitin Sulfate as a Pathogenetic Treatment of Osteoarthritis in the Context of Post-Genomic Studies
by: O. A. Gromova, et al.
Published: (2021-02-01)

REGULATORY AND METHODOLOGICAL ASPECTS OF STUDYING ALLERGENIC PROPERTIES OF NEW MEDICINES AT THE PRECLINICAL STAGE
by: K. L. Kryshen, et al.
Published: (2018-03-01)

CAR T-cells meet autoimmune neurological diseases: a new dawn for therapy
by: Nikolaos A. Chinas, et al.
Published: (2025-07-01)

ANALYSIS OF MANAGEMENT TACTICS IN THE TREATMENT OF PATIENTS WITH OSTEOARTHRITIS IN THE POPULATION OF THE REPUBLIC OF TAJIKISTAN
by: S. M. Shukurova, et al.
Published: (2017-04-01)

New approaches to early diagnosis of arthrosis and prospects for its pathogenetic therapy
by: Lilia Vladimirovna Luchikhina, et al.
Published: (2014-12-01)

Back pain: are there solutions?
by: E. S. Shishkina
Published: (2024-01-01)

Rheumatology in Karelia
by: V K Ignatyev, et al.
Published: (2004-06-01)

Problems of using phenol (hydroxybenzene) and parabens as pharmaceutical stabilizers: analysis using machine learning methods
by: I. Yu. Torshin, et al.
Published: (2025-05-01)

Differences in the standardization of medicinal products based on extracts of chondroitin sulfate
by: O. A. Gromova, et al.
Published: (2021-04-01)

Preclinical evaluation of tissue-engineered vascular grafts with biodegradable components: assessing the effectiveness of animal models from rats to primates
by: L. V. Antonova, et al.
Published: (2025-07-01)

Experience of local targeted administration of chondroprotective drugs into the zone of pathological changes in the labrum of the acetabulum in coxarthrosis
by: N. V. Sazonova, et al.
Published: (2021-06-01)

Advanced Therapy Medicines Based on Oncolytic Viruses (Part I: Development and Authorisation of Products in China)
by: E. V. Melnikova, et al.
Published: (2021-10-01)

NEW OPPORTUNITIES PHARMACOTHERAPY PATIENTS WITH REFRACTORY EPILEPSY
by: P. N. Vlasov
Published: (2017-03-01)

Advanced Therapy Medicines Based on Oncolytic Viruses (Part II: Development and Authorisation of IMLYGIC®)
by: E. V. Melnikova, et al.
Published: (2021-12-01)

Translating Basic Science to Clinical Applications: A Narrative Review of Repurposed Pharmacological Agents in Preclinical Models of Diabetic Neuropathy
by: Corina Andrei, et al.
Published: (2025-07-01)

The effectiveness of modern chondroprotective therapy in patients with degenerative-dystrophic diseases of the spine associated with pain in the lower back
by: N. V. Yakovleva
Published: (2023-06-01)

Efficacy and tolerability of methotrexate at a dose of 15 mg/week and 10 mg/week in patients with pulmonary sarcoidosis
by: V.K. Gavrysyuk, et al.
Published: (2021-12-01)

Evaluation of the antitumour activity of local intraperitoneal hyperthermia in a model of advanced high-grade ovarian carcinoma in rats
by: Ya. G. Murazov, et al.
Published: (2022-01-01)

SPECIFIC ASPECTS OF BENEFIT-RISK EVALUATION OF HERBAL MEDICINAL PRODUCTS: ANALYSIS OF REGISTRATION DOSSIERS
by: N. G. Olenina, et al.
Published: (2018-06-01)

Validation of Enzyme Immunoassay for Preclinical Pharmacokinetic Trials of Rituximab
by: V. V Pisarev, et al.
Published: (2019-06-01)

Experimental study of the acute toxicity of the oral form of pegylated interferon α2-b
by: D. N. Kinsht, et al.
Published: (2019-02-01)

Characteristics of sulfated glycosaminoglycans in the cartilage tissue of skate and sturgeon
by: A. I. Chepkasova, et al.
Published: (2023-01-01)

CURRENT PHARMACOTHERAPY FOR KNEE OSTEOARTHRITIS: SPECIFIC FEATURES OF SYMPTOMATIC AND DISEASE MODIFYING EFFECTS. COMMUNICATION 1. SPECIFIC FEATURES OF THE SYMPTOMATIC EFFECTS OF CURRENT DRUGS TO TREAT KNEE OSTHEOARTHRITIS
by: E. S. Tsvetkova, et al.
Published: (2015-03-01)

Pharmacoinformation studies of chondroprotectors
by: A. M. Lila, et al.
Published: (2021-10-01)

Anti-Tumour Drugs: Planning Preclinical Efficacy and Safety Studies
by: O, A. Bezborodova, et al.
Published: (2020-06-01)

Experience of applying a new European chondroprotector in patients with stage 1–2 osteoarthritis in general medical practice
by: T. N. Kargaeva
Published: (2021-06-01)

Preclinical and clinical development of preventive rotavirus vaccines: special considerations
by: A. S. Korovkin, et al.
Published: (2024-12-01)

The methodology of food design. Part 2. Digital nutritiology in personal food
by: A. Y. Prosekov, et al.
Published: (2022-01-01)

Recommendations for the Clinical Development of Medicinal Products for Non-specific Influenza Chemoprophylaxis
by: A. I. Gubenko, et al.
Published: (2024-04-01)

EXPERIENCE OF TREATMENT OF DIFFERENT FORMS OF EPILEPSY WITH GENERIC TOPIRAMATE (The results of focus observation in out-patientclinics network of Moscow city public healthcare services)
by: O. L. Badalyan, et al.
Published: (2016-09-01)

Evaluation of the Effectiveness of Nonspecific Medical Protection Against Diseased, Caused of Ebola Virus
by: T. E. Sizikova, et al.
Published: (2020-05-01)

METHODOLOGICAL APPROACHES TO EXPERT EVALUATION OF PRECLINICAL AND CLINICAL TRIALS OF HUMAN IMMUNOGLOBULIN PRODUCTS
by: V. B. Ivanov, et al.
Published: (2017-10-01)